The phenylketonuria (PKU) treatment market is anticipated to grow at a lucrative growth during the forecast period. PKU is a genetic metabolism defect that results in decreased metabolism of the amino acid called phenylalanine. PKU has no definite cure yet, it can only be managed using additional therapy and diet controls. Unmanaged PKU can lead to various intellectual disability, seizures, behavioral and mental disorders in children. In 2019, the global phenylketonuria treatment market was more than $570 million with a growth of around 22% YoY. Kuvan is a major drug for the treatment of phenylketonuria however by the fourth quarter of 2020, its generic version will be available in the US market. Due to these, a drop in the growth can be witnessed in the near future. The patent expiration offers considerable opportunities to the new market players in the US, Europe, and other regulated market.

Get Sample Copy of Phenylketonuria Treatment Market at: https://www.omrglobal.com/request-sample/phenylketonuria-treatment-market

The key players operating in the market include BioMarin Pharmaceutical Inc., Censa Pharmaceuticals Inc., Daiichi Sankyo Co. Ltd., Pluvia AS, Synlogic Inc., and others.

Moreover, the surge in the use of various gene and targeted therapy for the management of PKU is anticipated to significantly drive the phenylketonuria treatment market. In addition, the increasing R&D activities for the development of new effective drugs are also expected to fuel the growth of the phenylketonuria treatment market. In addition to this, pipeline drugs such as SYNB1618 and many more will also present new opportunities for the further expansion of the global phenylketonuria treatment market.

For More Information, get A full report of Phenylketonuria Treatment Market is available at: https://www.omrglobal.com/industry-reports/phenylketonuria-treatment-market

The global phenylketonuria treatment market is segmented based on drug type. The market is sub-segmented into kuvan, playnziq, and others. Among these, the kuvan sub-segment is anticipated to hold the largest market share during the forecast period. Kuvan was approved for the treatment of PKU by the US FDA in December 2007 and by the EU in December 2008. However, the drug will start to lose its patent from 2020. Playnziq is expected to show a significant growth rate during the forecast period as it was approved in May 2018 and will not lose any patent until 2025. Other segments will also segment with a lucrative growth with opportunity Is in new drug discoveries for the treatment of PKU during the forecast period.

Market Segmentation

Global Phenylketonuria Treatment Market by Drug Type
Kuvan
PlaynziqOthers


For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/phenylketonuria-treatment-market


About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com/

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 7803040404